Agilix Corp.
http://www.agilixcorp.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agilix Corp.
Start-Up Previews (4/04)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Microarrays, features Agilix Corp., Clinical MicroArrays Inc., GeneXP Biosciences Inc., Nanosphere Inc. and Spectral Genomics Inc. Plus these Start-Ups across Health Care: CoAxia Inc., eMembrane Inc. and Visiogen Inc.
Microarrays Aim for Center Stage
Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.
Agilix Corp.
Mid-stage clinical trial data rarely provide an easy answer on whether to advance a compound into complex and costly pivotal studies. Agilix Corp. has stepped into that void to offer gene expression analysis services using its GenCompass-a microarry-based expression profiling system that provides a rapid whole genome comparison between test and control subjects, providing data even about as yet uncharacterized genes.
Investing in Hard Times
VCs worried about depressed financial markets and demanding Big Pharma customers are being tough on almost all start-ups seeking funding-but no tougher than on their existing portfolio companies. For some, hard times are creating opportunities. The circumstances of companies that raised money in the past few years are impacting newer firms now. Even organizations that met their milestones have seen valuations plummet, and are struggling to get financing. The down market is making it more desirable and easier for VCs to invest in late-stage start-ups. In-licensing has been popular, but investors are increasingly seeking value-priced components to fill out existing firms or launch new ones. Investors haven't stopped doing early-stage deals, but they're looking for firms with advantages that can reduce risk or cost, or speed a company to market. Drugmakers that used to sign big-money deals are now demanding that start-ups prove their technologies' merits through short-term, inexpensive pilot programs. Some firms aren't so pressed by hard times. VCs are promising stellar founders lots of support and time to take big risks they bet will pay off handsomely.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice